哮喘患者使用双膦酸盐与股骨转子下及股骨干骨折风险:基于人群的巢式病例对照研究
该研究基于CPRD和HES数据库,在69,074名哮喘患者中识别67例非典型股骨转子下/股骨干骨折患者及260名匹配对照,发现双膦酸盐暴露与骨折风险升高相关(aOR=4.42,95%CI 2.98-8.53),长期使用(>5年)风险更高(aOR=7.67,95%CI 1.75-33.91),停药与风险降低相关。建议对哮喘患者定期审查双膦酸盐使用并权衡风险获益。
要点
- 哮喘患者使用双膦酸盐与非典型股骨转子下/股骨干骨折风险升高相关(aOR=4.42)。
- 长期使用超过5年者风险更高(aOR=7.67),停药与风险降低相关。
- 应定期审查哮喘患者的双膦酸盐治疗,并讨论前驱大腿痛等早期征象。
核心结论
- 哮喘患者使用双膦酸盐与非典型股骨转子下/股骨干骨折风险升高相关,长期使用风险更高,停药与风险降低相关。
- 建议对哮喘患者定期审查双膦酸盐治疗,并仔细权衡风险与获益。
研究设计与样本
- 基于CPRD和HES关联数据库的巢式病例对照研究,使用哮喘队列识别非典型股骨转子下/股骨干骨折患者及性别、年龄和诊所匹配的对照。
- 采用条件 logistic 回归分析双膦酸盐暴露与非典型股骨转子下/股骨干骨折之间的关联。
主要发现
- 从69,074名哮喘患者中识别出67例非典型股骨转子下/股骨干骨折患者和260名匹配对照。
- 病例组中40.3%接受过双膦酸盐治疗,对照组为14.2%,调整后比值比(aOR)为4.42(95%CI 2.98至8.53)。
- 长期使用(>5年 vs 无暴露)与非典型股骨转子下/股骨干骨折风险更高相关(aOR=7.67;95%CI 1.75至33.91)。
- 停药与非典型股骨转子下/股骨干骨折风险降低相关。
临床怎么用
- 对哮喘患者应定期审查双膦酸盐的使用。
- 与患者共同决策时需仔细考虑双膦酸盐治疗的风险与获益。
- 应讨论可能提示需要影像学检查的早期征象(如大腿前驱疼痛)以改善非典型股骨骨折的预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Concerns have been raised over the association between bisphosphonates and atypical fractures in subtrochanteric and femoral shaft regions, but the potential risk of these fractures due to bisphosphonate use in asthma has not been examined. INTRODUCTION: Bisphosphonates are used as first-line treatment for osteoporosis; however, concerns have been raised over their association with atypical subtrochanteric (ST) and femoral shaft (FS) fractures. The potential risk of atypical ST/FS fractures from bisphosphonate use in asthma has not been examined. METHODS: A nested case-control study was conducted using linked data from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) databases. Using an asthma cohort, we identified patients with atypical ST/FS fractures and sex, age, and practice-matched controls. Conditional logistic regression was used to determine the association between bisphosphonate exposure and atypical ST/FS fractures. RESULTS: From a cohort of 69,074 people with asthma, 67 patients with atypical ST/FS fractures and 260 matched control subjects were identified. Of the case patients, 40.3% had received bisphosphonates as compared with 14.2% of the controls corresponding to an adjusted odds ratio (aOR) of 4.42 (95%CI, 2.98 to 8.53). The duration of use influenced the risk with long-term users to be at a greater risk (> 5 years vs no exposure; aOR = 7.67; 95%CI, 1.75 to 33.91). Drug withdrawal was associated with diminished odds of atypical ST/FS fractures. CONCLUSION: Regular review of bisphosphonates should occur in patients with asthma. The risks and benefits of bisphosphonate therapy should be carefully considered in consultation with the patient. To improve AFF prevention, early signs which may warrant imaging, such as prodromal thigh pain, should be discussed.
引用
- Chalitsios CV, Shaw DE, McKeever TM, et al. Risk of subtrochanteric and femoral shaft fractures due to bisphosphonate therapy in asthma: a population-based nested case-control study. Osteoporos Int. 2021. PMID: 34635953. doi:10.1007/s00198-021-06197-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。